Advertisement Oxis appoints David Saloff as CEO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Oxis appoints David Saloff as CEO

Oxis, a US based biotechnology company that develops multiple proprietary, natural substance-based products focused on oxidative stress, has named David Saloff as the new CEO of the company.

In his career, he has founded three companies, two of which went public and a third that was sold to a healthcare products company.

Saloff was the co-founder and co-chief executive officer of Ivivi Technologies, which developed and manufactured advanced non-drug anti-inflammatory devices to treat chronic and acute wounds and post-surgical pain.

Oxis Chairman Anthony Cataldo said in addition to his managerial experience, David has an outstanding track record of effectively raising and deploying capital, and building shareholder value.